Topical corticosteroid fear is pushing dermatologists toward non-steroidal options in psoriasis, Dermatology Times reports in a new clinical feature on treatment selection.

The piece, titled "Addressing Steroid Fear with Non-Steroidal Treatment Options in Psoriasis," tackles a familiar problem in the plaque psoriasis clinic: patients who decline or abandon steroid creams over worries about skin thinning, withdrawal and long-term safety.

Why does steroid fear matter in psoriasis?

Plaque psoriasis is a chronic immune-mediated disease, and topical therapy remains the first-line route for most patients with limited body surface involvement. Corticosteroids have anchored that regimen for decades.

Patient reluctance changes the math. When prescriptions go unfilled or creams get stopped early, plaque clearance stalls and clinicians lose control of the disease trajectory. That makes the non-steroidal armamentarium a practical necessity, not a preference.

What non-steroidal options are on the table?

The Dermatology Times feature walks through the alternatives clinicians can reach for when a patient refuses steroids. The discussion centers on the non-steroidal topical classes now available for plaque psoriasis and how to sequence them.

The core message for prescribers: a steroid-free pathway exists, and raising it proactively can keep patients on therapy rather than out of treatment altogether.

How should clinicians handle the conversation?

The feature frames steroid fear as a counseling problem as much as a prescribing one. Dermatologists who acknowledge patient concerns directly, rather than dismissing them, are better positioned to negotiate a regimen the patient will actually use.

That negotiation matters for adherence. A treatment plan the patient distrusts is a treatment plan that fails quietly, between visits.

Dermatology Times points clinicians toward pairing honest risk discussion with concrete non-steroidal alternatives, so the choice becomes which steroid-sparing agent to start, not whether to treat at all.

The full feature is available through Dermatology Times.